|
The history of AIDS (Acquired Immunodeficiency Syndrome), with timelines, photos, and links to resources on the Internet. Endeavoring to raise public awareness through understanding.
|
|
The History of AIDS: Timeline of the History of HIV/AIDS: 1993 - 1994 1993 On May 7, FDA approved the Reality Female Condom which offers women a barrier product to protect themselves without relying on the cooperation of their partner. On September 10, FDA approved Megace (megestrol acetate) for a new indication for the treatment of anorexia, cachexia, or an unexplained weight loss in patients with AIDS. On December 14, FDA published an interim rule establishing a requirement for certain infectious disease testing, donor screening, and record keeping to help prevent the transmission of HIV and hepatitis b and C through human tissue used in transplantation. On December 17, FDA approved Neutrexin (trimetrexate glucuronate) for the treatment of moderate to severe Pneumocystis carinii pneumonia. On December 23, FDA approved Biaxin (clarithromycin) for a new indication for the treatment of disseminated mycobacterial infections due to Mycobacterium avium and Mycobacterium intracellular (Mycobacterium avium complex--MAC). On December 27, FDA licensed Gamimune (Immune Globulin Intravenous (Human), (IGIV)) for use in HIV-infected children (a new indication) to decrease the frequency of bacterial infections, increase the time free from serious bacterial infections, and decrease the frequency of hospitalizations. 1994 On January 7, FDA approved Bactrim and Septra (trimethoprim/sulfamethoxazole) for a new indication for prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. On February 4, Secretary Shalala announced the eighteen members of the National Task Force on AIDS Drug Development, which includes experts in AIDS drug development issues from academia, industry, medicine, the HIV/AIDS-affected communities, and Government. The Chairman of the Task Force is the Assistant Secretary for Health. FDA provides administrative and managerial support for the Task Force. On March 29, FDA asked condom manufacturers to begin using the air-burst test on all brands of latex condoms. This new test measures a condom's strength, and may be an indirect indicator of its resistance to breakage during use. On March 29, FDA approved Sporanox (itraconazole) capsules for a new indication for the treatment of pulmonary and extrapulmonary aspergillosis in patients who are intolerant of or who are refractory to amphotericin B therapy. On June 24, FDA approved Zerit (stavudine, d4T) for treatment of adults with HIV infection who no longer respond to or are intolerant of other antiviral drugs. On August 5, FDA approved new labeling for Hivid (zalcitabine, ddC) to include use as monotherapy for HIV-infection in adults. On August 8, FDA approved new labeling for Retrovir (zidovudine, AZT) to include use in preventing vertical transmission of HIV from HIV-infected pregnant women to their babies. On November 7, FDA approved a polyurethane condom for use by individuals who are allergic to latex. On November 23, FDA approved new labeling for Diflucan (fluconazole) to include pediatric patients with cryptococcal meningitis and candida infections. On December 20, FDA authorized pre-approval distribution of Serostim, a mammalian derived recombinant human growth hormone, under a treatment IND protocol to patients with AIDS-related wasting. On December 22, FDA approved Cytovene (oral ganciclovir) for the treatment of CMV retinitis in immunocompromised individuals. On December 23, FDA approved the first non blood-based collection kit utilizing oral fluid for use in the detection of the antibody to HIV-1. 1991 - 1992 ...Last ||| Next... 1995 |